TaiMed Biologics (4147.TWO) was invited to participate in the 2025 Taiwan Biotech Industry Summit Forum, where the company announced its latest corporate milestones and strategic plans. Among the key updates was the successful completion of the Phase 2a clinical trial for its long-acting antibody therapy, TMB-365/380, and the official initiation of Phase 2b studies. TaiMed also unveiled its active efforts to pursue global licensing and co-development partnerships.

TMB-365/380 is an innovative long-acting dual-antibody combination therapy designed to provide greater convenience and reduced side-effect risks for people living with HIV through a once-every-two-month injection regimen. According to the latest clinical data, 94% of patients achieved viral suppression (HIV RNA <50 copies/mL) within 24 weeks of treatment with no predefined virologic failure observed, demonstrating strong efficacy, safety, and tolerability.

The global HIV therapeutics market is projected to reach USD 43 billion by 2030, with long-acting therapies expected to account for over 30% of the market share. Backed by its unique mechanism of action and promising clinical profile,TMB-365/380 is positioned to become a next-generation, high-impact HIV treatment. Its initial target market includes an estimated 450,000 to 600,000 patients in the United States alone.

In addition,TaiMed announced plans to expand its antibody-drug conjugate (ADC) platform based on TMB-365 into the autoimmune disease space.The company intends to explore multiple autoimmune indications with significant unmet medical needs, with a combined potential market size exceeding USD 30 billion.

TaiMed is also strengthening its CDMO (Contract Development and Manufacturing Organization) operations, leveraging its in-house GMP-certified facilities to expand international business, enhance operational efficiency, and improve profitability.

Dr.Jimmy Chang,CEO of TaiMed Biologics, stated,“We are honored to participate in this year’s forum and share our strategic vision and key areas of development. Moving forward,TaiMed remains committed to advancing global patient care through scientific innovation, accelerating international collaborations for TMB-365/380 and our ADC platform, and enhancing long-term corporate competitiveness.”